Eristostatin, an RGD-containing disintegrin isolated from the venom of Eristicophis macmahoni, inhibits lung or liver colonization of melanoma cells in a mouse model. In this study, transwell migration and in vitro wound closure assays were used to determine the effect of eristostatin on the migration of melanoma cells. Eristostatin significantly impaired the migration of five human melanoma cell lines. Furthermore, it specifically inhibited cell migration on fibronectin in a concentration-dependent manner, but not that on collagen IV or laminin. In contrast, eristostatin was found to have no effect on cell proliferation or angiogenesis. These results indicate that the interaction between eristostatin and melanoma cells may involve fibronectin-binding integrins that mediate cell migration. Mutations to alanine of seven residues within the RGD loop of eristostatin and four residues outside the RGD loop of eristostatin resulted in significantly less potency in both platelet aggregation and wound closure assays. For six of the mutations, however, decreased activity was found only in the latter assay. We conclude that a different mechanism and/or integrin is involved in these two cell activities.
Introduction
Disintegrins are a family of low molecular weight and cysteine-rich proteins derived from viper venom. They were first identified as inhibitors of platelet aggregation and were subsequently shown to antagonize fibrinogen binding to platelet integrin aIIbb3 (Gould et al., 1990; Ouyang et al., 1983) .
Most disintegrins possess binding motifs (RGD, KGD, MVD, MLD, and VGD) similar to those found in fibronectin, fibrinogen and VCAM-1 (McLane et al., 2004) . They bind to various integrins with high affinity, and always inhibit the binding of the natural ligand. Although disintegrins are highly homologous, significant differences exist in their affinity and selectivity for integrins.
Eristostatin, a RGD-containing 49-residue disintegrin isolated from the venom of Eristicophis macmahoni, potently inhibits human platelet aggregation initiated by ADP .
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www.elsevier.com/locate/toxicon 0041-0101/$ -see front matter r 2007 Elsevier Ltd. All rights reserved. doi:10.1016 All rights reserved. doi:10. /j.toxicon.2006 Previous studies indicate eristostatin (at 25 mg/ mouse) inhibits liver and lung colonization when injected simultaneously with B16F10 murine melanoma cells into the tail vein of C57BL/6 mice (Beviglia et al., 1995; Morris et al., 1995) . Danen et al. (1998) found that eristostatin inhibits lung colonization following intravenous injection of MV3 human melanoma cells in nude mice, whereas we have demonstrated that eristostatin (at 10 mg/ mouse) inhibits lung colonization of two other human metastatic melanoma cells: M24met and C8161 (McLane et al., 2003) . The mechanism by which eristostatin inhibits murine and human melanoma cell functions is unknown.
Before cancer cells form a new tumor, they must escape from the primary site, enter the bloodstream, and survive blood flow. They must arrest in a distant organ, then survive and proliferate in the foreign microenvironment (Couzin, 2003) . Integrins are the major receptors for cell adhesion to extracellular matrix (ECM) proteins. Many of these metastatic steps involve integrin-ECM interaction, such as cell adhesion, migration, survival and proliferation at secondary sites (Giancotti, 1997; Jin and Varner., 2004) . Disintegrins bind to integrins and interfere with integrin function (McLane et al., 2004) . We propose that eristostatin prevents melanoma cell colonization of lung or liver via its blockage of integrin-ligand interaction.
In this study, we asked whether eristostatin modulates cell migration through integrins. Cell migration is known to involve integrins (Giancotti, 1997) and cell migration can contribute to tumor cell metastasis (Ridley et al., 2003) . In previous studies we showed that eristostatin significantly impaired wound closure in vitro by C8161 human melanoma cells (McLane et al., 2005) . We have confirmed this finding with four additional melanoma cell lines and identified av as an integrin subunit involved in the interaction with some, but not all, melanoma cells lines used. Structurally, both the RGD motif and residues within both the N-and C-terminus of eristostatin are critical for this interaction.
Materials and methods

Materials
Human melanoma cell lines 1205 Lu (metastatic), WM164 (vertical growth phase) and SBcl2 (radial growth phase) cells were kindly provided by Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA). Metastatic cell lines C8161 and MV3 were obtained from Fred Meyskens (University of California, Irvine Cancer Center) and Goos N.P.van Muijen (University Medical Center, Nijmegen, The Netherlands), respectively. M24met cells (metastatic) were from Ralph Reisfeld (The Scripps Institute, San Diego, CA). Dulbecco's modified eagle's medium/ham's F12 50:50 mix (DMEM) and Dulbecco's phosphate buffered saline (DPBS) were obtained from Mediatech (Herndon, VA), fetal bovine serum (FBS) was from GibcoBRL (Rockville, MD). Crude venom was obtained from Latoxan (Rosans, France). Albumin from bovine serum (BSA) was purchased from Sigma (St.Louis, MO). Fibronectin-coated 6-well plates were obtained from BD Biosciences (Bedford, MA), and 96-well PRO-BIND plates, from Becton Dickinson Labware (Franklin Lakes, NJ). Agar was purchased from BioRad Laboratories (Hercules, CA). Functional blocking antibodies against integrin av (clone M9, Cat. #MAB1980) and b1 (clone P5D2, Cat. #MAB 1959) chains were purchased from Chemicon (Temecula, CA). Transwell filters, 8.0 mm pore size and 6.5 mm in diameter, were obtained from Costar (Cambridge, MA).
Cell culture
All cell lines were maintained in DMEM containing 10% FBS at 37 1C and 5% CO 2 . Cells were grown to 80-90% confluence, detached using 2 mM EDTA, and centrifuged at 1200g for 5 min. After removal of media, cells were suspended in DPBS for use in proliferation and soft agar assays. For wound closure, time lapse, adhesion, and transwell migration assays, cells were washed twice and were resuspended with serum-free DMEM.
2.3. Preparation of native eristostatin and echistatin, recombinant eristostatin, and eristostatin mutants Native eristostatin and echistatin were isolated from crude venom of E. macmahoni and Echis carinatus sochurecki, respectively, by high performance liquid chromatography (HPLC) on a C-18 reversed phase column developed with an acetonitrile gradient as previously described .
Wild-type and mutant recombinant eristostatin were expressed in E. coli by a modification of the method previously described (Wierzbicka-Patynowski A u t h o r ' s p e r s o n a l c o p y et al., 1999) . Modification included the use of pET 39b (+) expression plasmid and isolation of the 6-histidine fusion protein with the His*Bind columns (Novagen, Madison, WI). Recombinant eristostatin clones were sequence-verified (DNA Sequencing Facility, University of Delaware, DE). Purity of recombinant eristostatin was assessed by SDS-PAGE, and molecular weight was confirmed by mass spectrometric analysis (Chemistry and Biochemistry Department, University of Delaware, DE).
Transwell migration assay
Transwell filters were equilibrated in serumcontaining DMEM for 2 h before use. DMEM containing 10% FBS was added to the lower compartments of the migration filters. In a volume of 100 ml serum-free DMEM, 2 Â 10 4 cells were plated per transwell filter. Cells were allowed to migrate for 6 h at 37 1C in 5% CO 2 , and were subsequently fixed by immersion of the filters in methanol for 15 min at room temperature. Filters were washed once with water, and were stained in 0.2% crystal violet in a 20% methanol/water solution for 10 min. Cells were removed from the upper surface of the membrane with a cotton swab. Cells that had migrated to the underside of the membrane were counted at 200 Â magnification from five random fields per membrane.
In vitro wound closure assays
Cells (2 Â 10 6 /well) were plated on fibronectincoated 6-well plates. After serum starvation for 24 h, the cells were scraped with a sterile 200 ml pipette tip and were washed twice with cold DPBS. Serum-free DMEM with or without eristostatin (0.5-3 mM) was added to each well. Measurements of the gap distance were taken with an ocular micrometer at each time point. The percent closure of untreated control was taken to be 100%. The percent closure of treated cells was calculated by dividing the distance that treated cells had migrated by the distance that untreated cells had migrated. A minimum of 9 observations for each cell type was made.
Time-lapse microscopy
Time-lapse wound closure assays were performed as described previously (Cretu et al., 2005) . In brief, cells were prepared and removed as described above using 3 mM eristostatin, and then abraded wells were placed in a custom culture chamber (37 1C and 5% CO 2 ) on a Nikon TE-2000E microscope. A Photometrics CoolSnap ES CCD camera (Roper Scientific, Inc.) was used to capture images on each plate at 5 min intervals for approximately 20 h under a 20 Â objective lens. Motility of cells was measured after collection of sequential time-lapse images. Cells which migrated back into the monolayer were excluded from the data collection. Analyses were performed on sequential phase-contrast images with MetaMorph software (Molecular Devices Corporation) manually using the ''Track Points'' feature, with individual nucleoli serving as imaging targets. Tabulated data were exported into Microsoft Excel, graphed, and evaluated statistically according to Student's two-tailed t-test.
Cell adhesion
PRO-BIND plates were coated with either recombinant eristostatin (1 mg in 100 ml) or 1% BSA and were incubated overnight at 4 1C. Plates were then blocked with 3% BSA in DMEM overnight at 4 1C, and were washed twice with DMEM containing 0.1% BSA. Cells were washed as described above and resuspended in DMEM containing 0.1% BSA at 2 Â 10 5 cells/ml. The cells were preincubated for 15 min at room temperature with function-blocking mAbs against human integrin av or b1 (10 mg/ml). Cells were added to the coated wells (2 Â 10 4 cells per well) and allowed to attach for 1 h at 37 1C, 5% CO 2 . Wells were washed twice with warm DMEM containing 0.1% BSA, and the attached cells were stained with 0.2% crystal violet in 20% methanol for 10 min. After washing, 0.5% Triton X-100 was used to lyse the cells and the absorbance was measured at 560 nm. Nonspecific binding (BSA-only wells) was subtracted from all values.
Proliferation assays
Cells (5 Â 10 3 ) were plated in 96-well plates in 10% serum-containing medium with or without 3 mM eristostatin for 0, 24 or 48 h. Cell proliferation was determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI) according to the manufacturer's instructions. p e r s o n a l c o p y 2.9. Soft agar assays Underlayers of 0.6% agar medium (1 ml) were prepared in 6-well plates by combining equal volumes of 1.2% noble agar and 2 Â DMEM with 20% FBS. 5 Â 10 3 cells were plated in 0.3% agar medium with or without 3 mM eristostatin. The surface was kept wet by addition of a small amount of DMEM containing 10% FBS. After 14 days, colonies formed were stained with 0.005% crystal violet and were counted at 25 Â magnification.
Angiogenesis in the embryonic quail chorioallantoic membrane (CAM)
Fertilized Japanese quail eggs (Coturnix coturnix japonica), cleaned with 70% ethanol, were maintained at 37 1C until embryonic day 3. The shells were opened with a razor blade and sterile scissors, and the contents were transferred into 6-well tissue culture plates prior to their return to the 37 1C incubator. At embryonic day 8, 0.5 ml of test compounds in PBS (20, 66 and 166 mg/ml) was applied drop-wise to coat the surface of the CAM, which covers the embryo, and were incubated for another 24 h. As the quail is not an inbred strain, there was some variability among embryos in the rate of growth and response to the test compounds. CAMs from eyeless or under-sized embryos were not used. After 24 h (on embryonic day 9), embryos were fixed with 5 ml of prewarmed 2% gluteraldehyde, 4% paraformaldehyde in PBS for 48 h at room temperature. Fixed CAMs were dissected from the surface of the embryo and mounted on glass slides in 10% polyvinyl alcohol, 25% glycerol in 0.5 M Tris, pH 8.5. The dried, mounted CAMs were photographed with a Nikon Microphot-SA digital camera microscope at 10 Â magnification. One 0.5 cm 2 /slide was recorded as an Adobe Photoshop image. No staining was necessary, as the arteries retained enough blood to render them semi-opaque. For comparison of arterial branching, composite figures were made from images that had been edited to remove veins and background. One field from each of three membranes per test solution was examined (Parsons-Wingerter et al., 1998).
Platelet aggregation
Disintegrin activity was screened by performing platelet aggregation with an ADP (20 mM) agonist, and was quantified by calculation of the IC 50 . Aspirin-free blood was collected from healthy donors in 3.2% (w/v) sodium citrate (1:9 ratio), and was centrifuged at 1300g for 10 min. Plateletrich plasma was separated from the cells within 30 min of collection. The concentration of each recombinant or native disintegrin that inhibited platelet aggregation by 50% was determined as described previously (Williams et al., 1990) .
Results
Migration of melanoma cells
To assess cell mobility in response to eristostatin, we performed transwell migration assays using serum-containing medium as the attractant in the lower well. As shown in Fig. 1 , the number of cells which migrated after exposure to eristostatin was significantly less than the control group for all melanoma cell lines.
The in vitro wound closure assays revealed a delayed closure on fibronectin matrix by eristostatin-treated human melanoma cells (Fig. 2(A) ). Cells that were treated with 3 mM eristostatin closed 56-88% of the area in comparison with untreated control cells on fibronectin matrix. Eristostatin had no effect on closure of MV3, 1205Lu, M24met or C8161 on laminin or collagen IV, with the exception ARTICLE IN PRESS Fig. 1 . Inhibition of cell migration by eristostatin. Indicated melanoma cells were plated on a transwell filter in the presence or absence of 3 mM eristostatin and allowed to migrate for 6 h. Migrated cells were counted microscopically. Data represents mean7standard error from two experiments (five random fields per experiment), *po0.05, Er-eristostatin.
A u t h o r ' s p e r s o n a l c o p y
of WM164. In the presence of different concentrations of recombinant eristostatin, migration of cells on fibronectin was affected by eristostatin in a concentration-dependent manner (Fig. 2(B) ) for all cell lines.
To evaluate the migration rate of treated vs. untreated cells, we performed a time lapse wound closure assay, in which photographs were taken at 5 min intervals while cells were migrating into the abraded area (Fig. 3, (A)-untreated, (B)-treated) . In contrast to motility of untreated cells, eristostatintreated cells exhibited a decreased rate, except for 1205Lu, which showed no difference in velocity between control and eristostatin treatment (Figs. 3(C) and (D), Movies 1-10).
Adhesion of melanoma cells
To determine which integrin subunit(s) was (were) involved in the interaction between eristostatin and the melanoma cells, we used functionblocking antibodies against integrin subunits av and b1 in an adhesion assay. Both anti-av and b1 IgGs showed an inhibitory effect on the adhesion of WM164 and SBcl2 cell lines to immobilized eristostatin, whereas only anti-av inhibited C8161 and 1205Lu cell adhesion (Fig. 4) . Neither antibody affected the adhesion M24met and MV3 cells.
Proliferation of melanoma cells
To determine whether eristostatin affected cell cycle, we measured the proliferation of cells by the use of an MTS assay. Eristostatin-treated cells showed no difference in cell number compared with control cells over 48 h (Fig. 5(A) ). We next determined the effects of eristostatin on the growth of melanoma cells in a three-dimensional soft agar environment. Melanoma cells were plated with or without 3 mM eristostatin within soft agar and were incubated for 2 weeks. Fig. 5(B) shows that the number of colonies formed by eristostatin-treated cells was similar to that of control cells. These results demonstrate that eristostatin has no effect on cell proliferation.
Angiogenesis
To evaluate the effect of eristostatin on angiogenesis, fertilized Japanese quail eggs (embryonic day 8) were treated with PBS containing echistatin or eristostatin (20-166 mg/ml). Twenty-four hours later, the blood vessels formed in the embryonic quail CAM were counted. There was no significant decrease in viability of the embryos, compared to PBS controls, in CAMs treated with the disintegrins, at doses up to 166 mg/ml. A significant decrease in arterial vessel density was seen in CAMs treated with echistatin at all concentrations tested, based on general morphological examination. CAMs treated with eristostatin were essentially equivalent to vehicle control (Figs. 6(A) and (B) ). 
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Effect of alanine mutagenesis on eristostatin function
To identify residues critical for the function of eristostatin, we made mutations to alanine in the disintegrin, based on residues that differ from those in echistatin, a disintegrin that does not inhibit melanoma metastasis (Danen et al., 1998) . The activities of the mutants were analyzed by in vitro wound closure assays and platelet aggregation. Residues Q1, E3 at the N-terminus, and D33 at the C-terminus, were not critical for the inhibition of cell migration of C8161 (Fig. 7(B) ) or ADPinduced platelet aggregation (Fig. 7(A) ), because they showed no significant differences from wildtype recombinant eristostatin in these two assays. In contrast, mutations of residues R24, V25, R27, G28, D29, W30 and N31 within the RGD loop, as well as ARTICLE IN PRESS 
Discussion
Many disintegrins, including echistatin (Hallak et al., 2005; Staiano et al., 1997) , contortrostatin (Swenson et al., 2004; Trikha et al., 1994; Zhou et al., 2000) , triflavin (Sheu et al., 1992 (Sheu et al., , 1994 , rhodostomin (Wiedle et al., 1999) and salmosin (Kang et al., 2000) are effective anti-tumor agents in vitro and/or in vivo. The most common molecular mechanism has been an inhibition of angiogenesis through integrins avb3, avb5 or a5b1. Kang et al., 1999; Marcinkiewicz et al., 2003; Markland et al., 2001; Olfa et al., 2005; Yeh et al., 1998 Yeh et al., , 2001 ). Eristostatin has also been shown to inhibit lung or liver colonization in vivo by either human or murine melanoma cells (Beviglia et al., 1995; Danen et al., 1998; McLane et al., 2004; Morris et al., 1995) . Our current data indicate that anti-angiogenesis cannot be a primary mechanism of eristostatin, because this disintegrin was not effective as an inhibitor of blood vessel growth in a CAM angiogenesis model (Fig. 6) . Thus far, the only integrins linked functionally with eristostatin have been aIIbb3 and a4b1 (Danen et al., 1998) . It is unlikely, however, that either aIIbb3 or a4b1 are common targets since these receptors are not expressed on all melanoma cell types tested in these studies (Wong et al., 2002) . The effect of eristostatin on cell migration was used in a screening assessment because this cellular activity is known to involve integrins. Inappropriate cell migration can also contribute to tumor cell metastasis. Eristostatin inhibited all melanoma cell lines tested in a transwell migration assay (Fig. 1) . We previously reported that eristostatin significantly impaired in vitro wound closure of C8161 human melanoma cells plated on fibronectin (McLane et al., 2005) . In this study, we have expanded that finding to include 4 additional human melanoma cell types: MV3, WM164, M24met, and 1205Lu, both at static time points (Fig. 2(A) ) and through time-lapse experiments (Fig. 3, videos 1-10 ). This phenomenon was concentration dependent (Fig. 2(B) ) and was selective for fibronectin in MV3, 1205Lu, M24met and C8161, all highly malignant melanoma cell lines (Fig. 2(A) ). Only the less malignant, vertical growth phase WM164 melanoma cells were affected by eristostatin on fibronectin, laminin and collagen IV (Fig. 2(A) ). Both cell migration and cell proliferation are important factors in this wound closure assay. Data from the MTS (Fig. 4(A) ) and soft-agar assays (Fig. 4(B) ) indicate that eristostatin has no effect on the proliferation of these melanoma cells, consistent with the study done by Morris et al. (1995) with B16F1 murine melanoma cells in vitro. These results strongly point to an effect of eristostatin only on cell migration, and a common mechanism involving fibronectin. (Table 1) (Hynes, 2002; Plow et al., 2000) , with nine recognizing the RGD sequence and three being nonRGD binding integrins. Previously we demonstrated that eristostatin abolishes the adhesion of melanoma cells to an immobilized RGD matrix (Pronectin-F s ), a result favoring an RGD-dependent mechanism (McLane et al., 2005) . In confirmation of this earlier observation, eristostatin lost its inhibitory effect on cell migration when residues R27, G28 and D29 were mutated (Fig. 7(B) ). It is interesting, however, that the initial adhesion of MV3 and M24met cells to the Pronectin-F s plates was weaker than was observed with C8161, 1205Lu or WM164 cells; therefore, the activity of eristostatin on these cells plated on fibronectin might not depend solely on the RGD motif. Although mutations in the RGD loop of eristostatin inhibit wound closure, it should be noted that alanine mutations of E2, T7 or R13 at the N-terminus, and W47, N48 or G49 at the C-terminus, also had a similar effect (Fig. 7(B) ). A comparison of the lack of effect on platelet aggregation by these six amino acids (Fig. 7(A) ) indicates that a different type of binding occurs with respect to the aIIbb3 integrin involved in platelets and the integrin mediating melanoma cell migration. Of the nine RGD-dependent, fibronectinbinding integrins, it is unlikely that either aIIbb3 or a5b1 is involved in interactions between eristostatin and the melanoma cells tested in this study. The fibrinogen receptor aIIbb3 is not expressed on any of these cell lines (Wong et al., 2002) . In addition, Beviglia et al. (1995) , and our own laboratory (Pfaff et al., 1994; WierzbickaPatynowski et al., 1999) , have shown that eristostatin Cell adhesion studies with antibodies to these integrin subunits (Fig. 4) indicate av as a common target for the interaction of C8161, WM164, SBcl2 and 1205Lu melanoma cells with eristostatin. It must be noted that the adhesion between eristostatin and MV3 or M24met is inhibited neither by anti-av nor anti-b1 antibodies, so these cells must use different integrin binding partners. In addition, MV3 cells do not express the b3 subunit (Danen et al., 1998) . Coupling this with the evidence that the latter two melanoma cell lines bound weakly to the RGDbased matrix on the Pronectin-F s plates suggests a potential nonRGD (and even nonintegrin) binding mechanism. These interesting possibilities are currently under investigation. Fig. 7 . Effect of eristostatin mutants in C8161 cell wound closure on fibronectin and on platelet aggregation. The same batch of recombinant eristostatin or its mutants was used to do both sets of experiments. (A) The IC 50 values of R27, G28, D29 and N31 were infinity because those mutants showed no inhibitory effect on ADP-induced platelet aggregation. (B) Activities of mutants assayed by C8161 in vitro wound closure on fibronectin. The percent closure was calculated as previously described. The values represent the means (7SE, vertical bars) of nine independent experiments, wtEr-wild type eristostatin; each amino acid is represent by a single-letter code, * indicates mutations with significant loss of inhibition in both assays. 
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